Sunesis Pharmaceuticals, Inc.
(NASDAQ : SNSS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
1.08%109.411.1%$637.77m
GILDGilead Sciences, Inc.
1.66%75.570.9%$577.68m
AMGNAmgen Inc.
1.13%176.901.1%$506.89m
REGNRegeneron Pharmaceuticals, Inc.
1.52%388.952.7%$352.74m
BIIBBiogen Inc.
1.36%327.941.2%$335.33m
ALXNAlexion Pharmaceuticals, Inc.
2.36%115.761.9%$262.11m
VRTXVertex Pharmaceuticals Incorporated
2.34%145.861.9%$218.93m
BLUEBluebird Bio, Inc.
-0.76%182.9516.1%$207.25m
ILMNIllumina, Inc.
2.70%216.553.5%$180.07m
ALNYAlnylam Pharmaceuticals, Inc
1.56%125.5910.0%$167.77m
AAgilent Technologies, Inc.
1.64%67.601.5%$158.47m
NKTRNektar Therapeutics
3.36%56.906.1%$157.89m
INCYIncyte Corporation
0.46%96.412.5%$142.11m
BMRNBioMarin Pharmaceutical Inc.
5.07%93.024.4%$114.48m
JUNOJuno Therapeutics, Inc.
1.16%44.6813.5%$102.38m

Company Profile

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.